Objectives: To investigate the efficacy of temozolomide (TMZ) in relationship to progression free survival at 6 months (PFS-6), median time to progression (TTP), response rate and toxicity, a phase II study was conducted in patients with recurrent glioblastoma multiforme (GBM) following surgery plus radiotherapy and a first-line regimen based on nitrosourea, procarbazine and vincristine. Methods: Forty-two patients with GBM were administered TMZ at the dose of 150 mg/m2/daily for 5 days every 4 weeks. Results: The PFS-6 and at 12 months (PFS-12) was 24% (95% Confidence Interval [CI] = 14–42%) and 8% (CI = 2–27%), respectively, with a median TTP of 11.7 weeks (CI = 9–22 weeks). The response was assessed in all 42 patients; we observed 2 complete responses (CR) (4.7%), 6 partial responses (PR) (14.3%), and 9 stable disease (SD) (21.4%), with CR+PR = 19% (CI = 7–31%). Conclusion: TMZ as a second line regimen is a valid option in patients with heavily pretreated GBM.

Brandes AA, Fiorentino M: The role of chemotherapy in recurrent malignant gliomas: an overview. Cancer Invest 1996;14:547–555.
Brandes AA, Vastola F, Monfardini S: Re-operation in recurrent high grade gliomas: literature review of prognostic factors and outcome. Am J Clin Oncol 1999;22:387–390.
Levin VA, Prados MD: Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance. J Clin Oncol 1992;10:766–771.
Yung WK, Metchler L, Gleason MJ: Intravenous carboplatin for recurrent malignant glioma: a phase II study. J Clin Oncol 1991;9:860–864.
Brandes AA, Pasetto LM, Vastola F, Monfardini S: Temozolomide in patients with high grade gliomas. Oncology 2000;59:181–186.
Newlands ES, Blackledge GRP, Slack JA, Rustin GJ, Smith DB, Stuart NSA, Quaterman CP, Hoffman R, Stevens MF, Brampton MH: Phase I trial of temozolomide. Br J Cancer 1992;65:287–291.
Friedman HS, Mc Lendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, Ashley DM, Krischer J, Lovell S, Rasheed K, Marchev F, Seman AJ, Cokgor I, Rich J, Stewart E, Colvin OM, Provenzale JM, Bigner DD, Haglund MM, Friedman AH, Modrich PL: DNA mismatch repair and O6-alkylguanine-DNA-alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 1998;16:3851–3857.
Tentori L, Graziani G, Gilberti S, Lacal PM, Bonmassar E, D’Atri S: Triazene compounds induce apoptosis in O6-alkylguanine-DNA-alkyltransferase deficient leukemia cell lines. Leukemia 1995;9:1888–1895.
Burger PC, Vogel FS, Green SB, Strike TA: Glioblastoma multiforme and AA: pathologic criteria and prognostic implications. Cancer 1985;56:1106–1110.
WHO Handbook for reporting results of cancer treatment. WHO offset publication. Neoplasma 1980;48:20:37–46.
Kaplan EL, Meier P: Non parametric estimation for incomplete observation. J Am Stat Assoc 1958;53:457–481.
Cox DR: Regression models and life tables. JR Stat Soc 1972;34:187–202.
Macdonald DR, Cascino TL, Schold C, Cairncross JG: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277–1280.
Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WKA: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999;17:2572–2578.
Yung A, Albright R, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000;83:588–593.
Brada M, Hoang-Xuan K, Rampling R, Dietrich P-Y, Dirix LY, Macdonald D, Heimans JJ, Zonnenberg BA, Bravo-Marques JM, Henriksson R, Stupp R, Yue N, Bruner J, Dugan M, Rao S, Zaknoen S: Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 2001;12:259–266.
Smith JS, Perry A, Borell TJ, Lee HK, O’Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW, Jenkins RB: Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000;18:636–645.
Osoba D, Aaronson NK, Muller M, Sneeuw K, Hsu MA, Yung WKA, Brada M, Newlands E: Effect of neurological dysfunction on health related quality of life in patients with high grade glioma. J Neuroncol 1997;34:263–278.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.